{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T13:04:35Z","timestamp":1780319075155,"version":"3.54.1"},"reference-count":40,"publisher":"The Pediatric Pharmacy Association","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022]]},"abstract":"\n OBJECTIVE<\/jats:title>\n Although vancomycin dosage recommendations in the pediatric setting for methicillin-resistant Staphylococcus aureus<\/jats:italic> (MRSA) infection indicate that \u226560 mg\/kg\/day is correlated to a desired area under the vancomycin concentration time curve from 0 to 24 hours to minimum inhibitory concentration ratio (AUC0\u201324 hr<\/jats:sub>\/MIC) \u2265400, for some patients this dosage is inadequate or relates to toxicity. This study purposed to explore vancomycin dosing for pediatrics with various degrees of renal function.<\/jats:p>\n <\/jats:sec>\n \n METHODS<\/jats:title>\n Routine monitoring data were retrospectively collected from patients, aged 1 month to 18 years. Population pharmacokinetic analysis was performed by using non-linear mixed-effect model with NONMEM software, and Monte Carlo simulation was conducted by using Crystal Ball software.<\/jats:p>\n <\/jats:sec>\n \n RESULTS<\/jats:title>\n Two hundred twelve patients with 348 vancomycin serum concentrations were included. Median age was 3.5 years (IQR, 0.9\u201310.9), median weight was 14.0 kg (IQR, 7.2\u201330.4), with baseline estimated glomerular filtration rate (eGFR) ranging from 15.5 to 359.3 mL\/min\/1.73 m2<\/jats:sup>. A 1-compartment model with first-order elimination sufficiently described vancomycin PK. The dosing targeting AUC0\u201324hr<\/jats:sub>\/MIC \u2265400 and AUC0\u201324hr<\/jats:sub> <800 mg\u2022h\/L for pediatric patients with eGFRs of 15 to 29, 30 to 59, 60 to 89, 90 to 129, and 130 to 160 mL\/min\/1.73 m2<\/jats:sup> was 12.5, 25, 40, 60, and 70 mg\/kg\/day, respectively. All vancomycin dosing obtained >85% of the cumulative fraction of response across the MIC distribution of MRSA.<\/jats:p>\n <\/jats:sec>\n \n CONCLUSIONS<\/jats:title>\n Vancomycin dosing of 12.5, 25, 40, 60, and 70 mg\/kg\/day is suggested for pediatric patients with eGFRs of 15 to 29, 30 to 59, 60 to 89, 90 to 129, and 130 to 160 mL\/min\/1.73 m2<\/jats:sup>, respectively.<\/jats:p>\n <\/jats:sec>","DOI":"10.5863\/1551-6776-27.5.419","type":"journal-article","created":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T14:51:54Z","timestamp":1657119114000},"page":"419-427","source":"Crossref","is-referenced-by-count":5,"title":["Population Pharmacokinetics and Pharmacodynamics of Vancomycin in Pediatric Patients With Various Degrees of Renal Function"],"prefix":"10.5863","volume":"27","author":[{"given":"Chanika","family":"Chuphan","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice (CC, TW), Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waroonrat","family":"Sukarnjanaset","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Care (WS), College of Pharmacy, Rangsit University, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thanyawee","family":"Puthanakit","sequence":"additional","affiliation":[{"name":"Department of Pediatrics (TP), Center of Excellence for Pediatric Infectious Diseases and Vaccines, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thitima","family":"Wattanavijitkul","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice (CC, TW), Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3883","reference":[{"issue":"3","key":"i2331-348X-27-5-419-b1","series-title":"Clin Infect Dis","first-page":"285","article-title":"Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary","volume":"52","year":"2011","unstructured":"Liu\n C,\n \n \n Bayer\n A,\n \n \n Cosgrove\n SE,\n \n \n .\n\t\t\t\t\tClinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary.\n\t\t\t\t\tClin Infect Dis.\n\t\t\t\t\t2011;\n\t\t\t\t\t52(\n\t\t\t\t\t3):\n\t\t\t\t\t285\u2013\n\t\t\t\t\t292."},{"issue":"2","key":"i2331-348X-27-5-419-b2","series-title":"Clin Infect Dis","first-page":"e10","article-title":"Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America","volume":"59","year":"2014","unstructured":"Stevens\n DL,\n \n \n Bisno\n AL,\n \n \n Chambers\n HF,\n \n \n .\n\t\t\t\t\tPractice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America.\n\t\t\t\t\tClin Infect Dis.\n\t\t\t\t\t2014;\n\t\t\t\t\t59(\n\t\t\t\t\t2):\n\t\t\t\t\te10\u2013\n\t\t\t\t\te52."},{"issue":"3","key":"i2331-348X-27-5-419-b3","series-title":"J Health Syst Res","first-page":"352","article-title":"Health and economic impacts of antimicrobial resistant infections in Thailand: a preliminary study","volume":"6","year":"2012","unstructured":"Phumart\n P,\n \n \n Phodha\n T,\n \n \n Thammalikitkul\n V,\n \n \n .\n\t\t\t\t\tHealth and economic impacts of antimicrobial resistant infections in Thailand: a preliminary study.\n\t\t\t\t\tJ Health Syst Res.\n\t\t\t\t\t2012;\n\t\t\t\t\t6(\n\t\t\t\t\t3):\n\t\t\t\t\t352\u2013\n\t\t\t\t\t360."},{"key":"i2331-348X-27-5-419-b4","article-title":"Antimicrobial resistance global report on surveillance","year":"2014","unstructured":"World Health Organization.\n\t\t\t\t\t\n Antimicrobial resistance global report on surveillance.\n\t\t\t\t\t2014.\n\t\t\t\t\tAccessed December 5, 2020. https:\/\/www.who.int\/drugresistance\/documents\/surveillancereport\/en\/"},{"issue":"11","key":"i2331-348X-27-5-419-b5","series-title":"Am J Health Syst Pharm","first-page":"835","article-title":"Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists","volume":"77","year":"2020","unstructured":"Rybak\n MJ,\n \n \n Le\n J,\n \n \n Lodise\n TP,\n \n \n .\n\t\t\t\t\tTherapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists.\n\t\t\t\t\tAm J Health Syst Pharm.\n\t\t\t\t\t2020;\n\t\t\t\t\t77(\n\t\t\t\t\t11):\n\t\t\t\t\t835\u2013\n\t\t\t\t\t864."},{"issue":"13","key":"i2331-348X-27-5-419-b6","series-title":"Clin Pharmacokinet","first-page":"925","article-title":"Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections","volume":"43","year":"2004","unstructured":"Moise-Broder\n PA,\n \n \n Forrest\n A,\n \n \n Birmingham\n MC,\n \n \n Schentag\n JJ.\n \n \n Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections.\n\t\t\t\t\tClin Pharmacokinet.\n\t\t\t\t\t2004;\n\t\t\t\t\t43(\n\t\t\t\t\t13):\n\t\t\t\t\t925\u2013\n\t\t\t\t\t942."},{"issue":"11","key":"i2331-348X-27-5-419-b7","series-title":"Eur J Clin Pharmacol","first-page":"1341","article-title":"Determining the optimal vancomycin daily dose for pediatrics: a meta-analysis","volume":"73","year":"2017","unstructured":"da Silva Alves\n GC,\n \n \n da Silva\n SD,\n \n \n Frade\n VP,\n \n \n .\n\t\t\t\t\tDetermining the optimal vancomycin daily dose for pediatrics: a meta-analysis.\n\t\t\t\t\tEur J Clin Pharmacol.\n\t\t\t\t\t2017;\n\t\t\t\t\t73(\n\t\t\t\t\t11):\n\t\t\t\t\t1341\u2013\n\t\t\t\t\t1353."},{"issue":"6","key":"i2331-348X-27-5-419-b8","series-title":"J Clin Pharm Ther","first-page":"1278","article-title":"Vancomycin population pharmacokinetics and dosing recommendations in haematologic malignancy with augmented renal clearance children","volume":"45","year":"2020","unstructured":"Lv\n CL,\n \n \n Lu\n JJ,\n \n \n Chen\n M,\n \n \n .\n\t\t\t\t\tVancomycin population pharmacokinetics and dosing recommendations in haematologic malignancy with augmented renal clearance children.\n\t\t\t\t\tJ Clin Pharm Ther.\n\t\t\t\t\t2020;\n\t\t\t\t\t45(\n\t\t\t\t\t6):\n\t\t\t\t\t1278\u2013\n\t\t\t\t\t1287."},{"issue":"4","key":"i2331-348X-27-5-419-b9","series-title":"Antimicrob Agents Chemother","first-page":"1330","article-title":"Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity","volume":"52","year":"2008","unstructured":"Lodise\n TP,\n \n \n Lomaestro\n B,\n \n \n Graves\n J,\n \n \n Drusano\n GL.\n \n \n Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity.\n\t\t\t\t\tAntimicrob Agents Chemother.\n\t\t\t\t\t2008;\n\t\t\t\t\t52(\n\t\t\t\t\t4):\n\t\t\t\t\t1330\u2013\n\t\t\t\t\t1336."},{"issue":"7","key":"i2331-348X-27-5-419-b10","series-title":"Pharmacotherapy","first-page":"662","article-title":"Comparison of acute kidney injury during treatment with vancomycin in combination with piperacillin-tazobactam or cefepime","volume":"34","year":"2014","unstructured":"Gomes\n DM,\n \n \n Smotherman\n C,\n \n \n Birch\n A,\n \n \n .\n\t\t\t\t\tComparison of acute kidney injury during treatment with vancomycin in combination with piperacillin-tazobactam or cefepime.\n\t\t\t\t\tPharmacotherapy.\n\t\t\t\t\t2014;\n\t\t\t\t\t34(\n\t\t\t\t\t7):\n\t\t\t\t\t662\u2013\n\t\t\t\t\t669."},{"key":"i2331-348X-27-5-419-b11","series-title":"BMC Res Notes","first-page":"579","article-title":"Risk factors for kidney injury during vancomycin and piperacillin\/tazobactam administration, including increased odds of injury with combination therapy","volume":"8","year":"2015","unstructured":"Kim\n T,\n \n \n Kandiah\n S,\n \n \n Patel\n M,\n \n \n .\n\t\t\t\t\tRisk factors for kidney injury during vancomycin and piperacillin\/tazobactam administration, including increased odds of injury with combination therapy.\n\t\t\t\t\tBMC Res Notes.\n\t\t\t\t\t2015;\n\t\t\t\t\t8:\n\t\t\t\t\t579."},{"issue":"3","key":"i2331-348X-27-5-419-b12","series-title":"Clin Ther","first-page":"494","article-title":"Impact of an antimicrobial stewardship program on patient safety in veterans prescribed vancomycin","volume":"38","year":"2016","unstructured":"Fodero\n KE,\n \n \n Horey\n AL,\n \n \n Krajewski\n MP,\n \n \n .\n\t\t\t\t\tImpact of an antimicrobial stewardship program on patient safety in veterans prescribed vancomycin.\n\t\t\t\t\tClin Ther.\n\t\t\t\t\t2016;\n\t\t\t\t\t38(\n\t\t\t\t\t3):\n\t\t\t\t\t494\u2013\n\t\t\t\t\t502."},{"issue":"1","key":"i2331-348X-27-5-419-b13","series-title":"Antimicrob Agents Chemother","first-page":"e01684","article-title":"Identification of vancomycin exposure-toxicity thresholds in hospitalized patients receiving intravenous vancomycin","volume":"62","year":"2018","unstructured":"Zasowski\n EJ,\n \n \n Murray\n KP,\n \n \n Trinh\n TD,\n \n \n .\n\t\t\t\t\tIdentification of vancomycin exposure-toxicity thresholds in hospitalized patients receiving intravenous vancomycin.\n\t\t\t\t\tAntimicrob Agents Chemother.\n\t\t\t\t\t2018;\n\t\t\t\t\t62(\n\t\t\t\t\t1):\n\t\t\t\t\te01684\u2013\n\t\t\t\t\t17."},{"issue":"4","key":"i2331-348X-27-5-419-b14","series-title":"Chemotherapy","first-page":"308","article-title":"Is peak concentration needed in therapeutic drug monitoring of vancomycin? A pharmacokinetic-pharmacodynamic analysis in patients with methicillin-resistant Staphylococcus aureus pneumonia","volume":"58","year":"2012","unstructured":"Suzuki\n Y,\n \n \n Kawasaki\n K,\n \n \n Sato\n Y,\n \n \n .\n\t\t\t\t\tIs peak concentration needed in therapeutic drug monitoring of vancomycin? A pharmacokinetic-pharmacodynamic analysis in patients with methicillin-resistant Staphylococcus aureus pneumonia.\n\t\t\t\t\tChemotherapy.\n\t\t\t\t\t2012;\n\t\t\t\t\t58(\n\t\t\t\t\t4):\n\t\t\t\t\t308\u2013\n\t\t\t\t\t312."},{"issue":"1","key":"i2331-348X-27-5-419-b15","series-title":"Antimicrob Agents Chemother","first-page":"309","article-title":"Are vancomycin trough concentrations adequate for optimal dosing?","volume":"58","year":"2014","unstructured":"Neely\n MN,\n \n \n Youn\n G,\n \n \n Jones\n B,\n \n \n .\n\t\t\t\t\tAre vancomycin trough concentrations adequate for optimal dosing?Antimicrob Agents Chemother.\n\t\t\t\t\t2014;\n\t\t\t\t\t58(\n\t\t\t\t\t1):\n\t\t\t\t\t309\u2013\n\t\t\t\t\t316."},{"issue":"4","key":"i2331-348X-27-5-419-b16","series-title":"J Pediatric Infect Dis Soc","first-page":"e109","article-title":"Pharmacodynamic characteristics of nephrotoxicity associated with vancomycin use in children","volume":"4","year":"2015","unstructured":"Le\n J,\n \n \n Ny\n P,\n \n \n Capparelli\n E,\n \n \n .\n\t\t\t\t\tPharmacodynamic characteristics of nephrotoxicity associated with vancomycin use in children.\n\t\t\t\t\tJ Pediatric Infect Dis Soc.\n\t\t\t\t\t2015;\n\t\t\t\t\t4(\n\t\t\t\t\t4):\n\t\t\t\t\te109\u2013\n\t\t\t\t\te116."},{"issue":"6","key":"i2331-348X-27-5-419-b17","series-title":"Eur J Drug Metab Pharmacokinet","first-page":"729","article-title":"Evaluation of FOCEI and SAEM estimation methods in population pharmacokinetic analysis using NONMEM\u00ae across rich, medium, and sparse sampling data","volume":"43","year":"2018","unstructured":"Sukarnjanaset\n W,\n \n \n Wattanavijitkul\n T,\n \n \n Jarurattanasirikul\n S.\n \n \n Evaluation of FOCEI and SAEM estimation methods in population pharmacokinetic analysis using NONMEM\u00ae across rich, medium, and sparse sampling data.\n\t\t\t\t\tEur J Drug Metab Pharmacokinet.\n\t\t\t\t\t2018;\n\t\t\t\t\t43(\n\t\t\t\t\t6):\n\t\t\t\t\t729\u2013\n\t\t\t\t\t736."},{"issue":"3","key":"i2331-348X-27-5-419-b18","series-title":"J Am Soc Nephrol","first-page":"629","article-title":"New equations to estimate GFR in children with CKD","volume":"20","year":"2009","unstructured":"Schwartz\n GJ,\n \n \n Munoz\n A,\n \n \n Schneider\n MF,\n \n \n .\n\t\t\t\t\tNew equations to estimate GFR in children with CKD.\n\t\t\t\t\tJ Am Soc Nephrol.\n\t\t\t\t\t2009;\n\t\t\t\t\t20(\n\t\t\t\t\t3):\n\t\t\t\t\t629\u2013\n\t\t\t\t\t637."},{"issue":"5","key":"i2331-348X-27-5-419-b19","series-title":"Nephrol Dial Transplant","first-page":"798","article-title":"An estimated glomerular filtration rate equation for the full age spectrum","volume":"31","year":"2016","unstructured":"Pottel\n H,\n \n \n Hoste\n L,\n \n \n Dubourg\n L,\n \n \n .\n\t\t\t\t\tAn estimated glomerular filtration rate equation for the full age spectrum.\n\t\t\t\t\tNephrol Dial Transplant.\n\t\t\t\t\t2016;\n\t\t\t\t\t31(\n\t\t\t\t\t5):\n\t\t\t\t\t798\u2013\n\t\t\t\t\t806."},{"issue":"6","key":"i2331-348X-27-5-419-b20","series-title":"Pediatr Nephrol","first-page":"973","article-title":"A simple height-independent equation for estimating glomerular filtration rate in children","volume":"27","year":"2012","unstructured":"Pottel\n H,\n \n \n Hoste\n L,\n \n \n Martens\n F.\n \n \n A simple height-independent equation for estimating glomerular filtration rate in children.\n\t\t\t\t\tPediatr Nephrol.\n\t\t\t\t\t2012;\n\t\t\t\t\t27(\n\t\t\t\t\t6):\n\t\t\t\t\t973\u2013\n\t\t\t\t\t979."},{"issue":"1","key":"i2331-348X-27-5-419-b21","series-title":"J Pharmacol Clin Toxicol","first-page":"1017","article-title":"Population-based pharmacokinetic modeling of vancomycin in children with renal insufficiency","volume":"2","year":"2014","unstructured":"Le\n J,\n \n \n Vaida\n F,\n \n \n Nguyen\n E,\n \n \n .\n\t\t\t\t\tPopulation-based pharmacokinetic modeling of vancomycin in children with renal insufficiency.\n\t\t\t\t\tJ Pharmacol Clin Toxicol.\n\t\t\t\t\t2014;\n\t\t\t\t\t2(\n\t\t\t\t\t1):\n\t\t\t\t\t1017\u2013\n\t\t\t\t\t1026."},{"key":"i2331-348X-27-5-419-b22","article-title":"Vancomycin. Lexicomp online","unstructured":"Vancomycin. Lexicomp online.\n\t\t\t\t\tHudson, OH:\n\t\t\t\t\tWolters Kluwer Health, Inc.\n\t\t\t\t\tUpdated July 1, 2020. Accessed December 5, 2020. https:\/\/online.lexi.com"},{"key":"i2331-348X-27-5-419-b23","article-title":"European Committee on Antimicrobial Susceptibility Testing. Antimicrobial wild type distributions of micro-organisms","year":"2020","unstructured":"European Committee on Antimicrobial Susceptibility Testing. Antimicrobial wild type distributions of micro-organisms.\n\t\t\t\t\t2020.\n\t\t\t\t\tAccessed December 5, 2020. https:\/\/mic.eucast.org\/Eucast2\/"},{"issue":"5","key":"i2331-348X-27-5-419-b24","series-title":"Pediatrics","first-page":"e20153492","article-title":"Infant BMI or weight-for-length and obesity risk in early childhood","volume":"137","year":"2016","unstructured":"Roy\n SM,\n \n \n Spivack\n JG,\n \n \n Faith\n MS,\n \n \n .\n\t\t\t\t\tInfant BMI or weight-for-length and obesity risk in early childhood.\n\t\t\t\t\tPediatrics.\n\t\t\t\t\t2016;\n\t\t\t\t\t137(\n\t\t\t\t\t5):\n\t\t\t\t\te20153492."},{"key":"i2331-348X-27-5-419-b25","article-title":"About child & teen BMI","year":"2020","unstructured":"Centers for Disease Control and Prevention.\n\t\t\t\t\t\n About child & teen BMI.\n\t\t\t\t\t2020.\n\t\t\t\t\tAccessed August 28, 2020. https:\/\/www.cdc.gov\/healthyweight\/assessing\/bmi\/childrens_bmi\/about_childrens_bmi.html"},{"issue":"4","key":"i2331-348X-27-5-419-b26","series-title":"Pediatr Infect Dis J","first-page":"e155","article-title":"Improved vancomycin dosing in children using area under the curve exposure","volume":"32","year":"2013","unstructured":"Le\n J,\n \n \n Bradley\n JS,\n \n \n Murray\n W,\n \n \n .\n\t\t\t\t\tImproved vancomycin dosing in children using area under the curve exposure.\n\t\t\t\t\tPediatr Infect Dis J.\n\t\t\t\t\t2013;\n\t\t\t\t\t32(\n\t\t\t\t\t4):\n\t\t\t\t\te155\u2013\n\t\t\t\t\te163."},{"issue":"6","key":"i2331-348X-27-5-419-b27","series-title":"Antimicrob Agents Chemother","first-page":"3191","article-title":"Population pharmacokinetics and dosing optimization of vancomycin in children with malignant hematological disease","volume":"58","year":"2014","unstructured":"Zhao\n W,\n \n \n Zhang\n D,\n \n \n Fakhoury\n M,\n \n \n .\n\t\t\t\t\tPopulation pharmacokinetics and dosing optimization of vancomycin in children with malignant hematological disease.\n\t\t\t\t\tAntimicrob Agents Chemother.\n\t\t\t\t\t2014;\n\t\t\t\t\t58(\n\t\t\t\t\t6):\n\t\t\t\t\t3191\u2013\n\t\t\t\t\t3199."},{"issue":"1","key":"i2331-348X-27-5-419-b28","series-title":"J Clin Pharmacol","first-page":"77","article-title":"AUC-guided vancomycin dosing in adolescent patients with suspected sepsis","volume":"57","year":"2017","unstructured":"Lanke\n S,\n \n \n Yu\n T,\n \n \n Rower\n JE,\n \n \n .\n\t\t\t\t\tAUC-guided vancomycin dosing in adolescent patients with suspected sepsis.\n\t\t\t\t\tJ Clin Pharmacol.\n\t\t\t\t\t2017;\n\t\t\t\t\t57(\n\t\t\t\t\t1):\n\t\t\t\t\t77\u2013\n\t\t\t\t\t84."},{"issue":"6","key":"i2331-348X-27-5-419-b29","series-title":"Ther Drug Monit","first-page":"612","article-title":"Population pharmacokinetics of vancomycin in Japanese pediatric patients","volume":"20","year":"1998","unstructured":"Yasuhara\n M,\n \n \n Iga\n T,\n \n \n Zenda\n H,\n \n \n .\n\t\t\t\t\tPopulation pharmacokinetics of vancomycin in Japanese pediatric patients.\n\t\t\t\t\tTher Drug Monit.\n\t\t\t\t\t1998;\n\t\t\t\t\t20(\n\t\t\t\t\t6):\n\t\t\t\t\t612\u2013\n\t\t\t\t\t618."},{"issue":"6","key":"i2331-348X-27-5-419-b30","series-title":"Int J Clin Pharmacol Ther","first-page":"509","article-title":"Population pharmacokinetics of vancomycin in Chinese pediatric patients","volume":"55","year":"2017","unstructured":"Liu\n T,\n \n \n Deng\n C,\n \n \n Cheng\n D,\n \n \n .\n\t\t\t\t\tPopulation pharmacokinetics of vancomycin in Chinese pediatric patients.\n\t\t\t\t\tInt J Clin Pharmacol Ther.\n\t\t\t\t\t2017;\n\t\t\t\t\t55(\n\t\t\t\t\t6):\n\t\t\t\t\t509\u2013\n\t\t\t\t\t516."},{"issue":"5","key":"i2331-348X-27-5-419-b31","series-title":"Antimicrob Agents Chemother","first-page":"e00067","article-title":"Revising pediatric vancomycin dosing accounting for nephrotoxicity in a pharmacokinetic-pharmacodynamic model","volume":"63","year":"2019","unstructured":"Kloprogge\n F,\n \n \n Hill\n LF,\n \n \n Booth\n J,\n \n \n .\n\t\t\t\t\tRevising pediatric vancomycin dosing accounting for nephrotoxicity in a pharmacokinetic-pharmacodynamic model.\n\t\t\t\t\tAntimicrob Agents Chemother.\n\t\t\t\t\t2019;\n\t\t\t\t\t63(\n\t\t\t\t\t5):\n\t\t\t\t\te00067-\n\t\t\t\t\t19."},{"issue":"8","key":"i2331-348X-27-5-419-b32","series-title":"Eur J Clin Pharmacol","first-page":"1089","article-title":"Population pharmacokinetic analysis of vancomycin in pediatric continuous renal replacement therapy","volume":"75","year":"2019","unstructured":"Moffett\n BS,\n \n \n Morris\n J,\n \n \n Munoz\n F,\n \n \n Arikan\n AA.\n \n \n Population pharmacokinetic analysis of vancomycin in pediatric continuous renal replacement therapy.\n\t\t\t\t\tEur J Clin Pharmacol.\n\t\t\t\t\t2019;\n\t\t\t\t\t75(\n\t\t\t\t\t8):\n\t\t\t\t\t1089\u2013\n\t\t\t\t\t1097."},{"issue":"6","key":"i2331-348X-27-5-419-b33","series-title":"Clin Ther","first-page":"1340","article-title":"Bayesian estimation of vancomycin pharmacokinetics in obese children: Matched case-control study","volume":"37","year":"2015","unstructured":"Le\n J,\n \n \n Capparelli\n EV,\n \n \n Wahid\n U,\n \n \n .\n\t\t\t\t\tBayesian estimation of vancomycin pharmacokinetics in obese children: Matched case-control study.\n\t\t\t\t\tClin Ther.\n\t\t\t\t\t2015;\n\t\t\t\t\t37(\n\t\t\t\t\t6):\n\t\t\t\t\t1340\u2013\n\t\t\t\t\t1351."},{"issue":"1","key":"i2331-348X-27-5-419-b34","series-title":"Br J Clin Pharmacol","first-page":"75","article-title":"Vancomycin pharmacokinetics in preterm neonates and the prediction of adult clearance","volume":"63","year":"2007","unstructured":"Anderson\n BJ,\n \n \n Allegaert\n K,\n \n \n Van den Anker\n JN,\n \n \n .\n\t\t\t\t\tVancomycin pharmacokinetics in preterm neonates and the prediction of adult clearance.\n\t\t\t\t\tBr J Clin Pharmacol.\n\t\t\t\t\t2007;\n\t\t\t\t\t63(\n\t\t\t\t\t1):\n\t\t\t\t\t75\u2013\n\t\t\t\t\t84."},{"issue":"2","key":"i2331-348X-27-5-419-b35","series-title":"J Pediatr Pharmacol Ther","first-page":"107","article-title":"Population pharmacokinetics of vancomycin in the pediatric cardiac surgical population","volume":"24","year":"2019","unstructured":"Moffett\n BS,\n \n \n Resendiz\n K,\n \n \n Morris\n J,\n \n \n .\n\t\t\t\t\tPopulation pharmacokinetics of vancomycin in the pediatric cardiac surgical population.\n\t\t\t\t\tJ Pediatr Pharmacol Ther.\n\t\t\t\t\t2019;\n\t\t\t\t\t24(\n\t\t\t\t\t2):\n\t\t\t\t\t107\u2013\n\t\t\t\t\t116."},{"issue":"1","key":"i2331-348X-27-5-419-b36","series-title":"Pediatr Nephrol","first-page":"25","article-title":"Augmented renal clearance in pediatric intensive care: are we undertreating our sickest patients?","volume":"35","year":"2020","unstructured":"Dhont\n E,\n \n \n Van Der Heggen\n T,\n \n \n De Jaeger\n A,\n \n \n .\n\t\t\t\t\tAugmented renal clearance in pediatric intensive care: are we undertreating our sickest patients?Pediatr Nephrol.\n\t\t\t\t\t2020;\n\t\t\t\t\t35(\n\t\t\t\t\t1):\n\t\t\t\t\t25\u2013\n\t\t\t\t\t39."},{"issue":"6","key":"i2331-348X-27-5-419-b37","series-title":"Pediatr Nephrol","first-page":"1099","article-title":"Augmented renal clearance: a common condition in critically ill children","volume":"34","year":"2019","unstructured":"Van Der Heggen\n T,\n \n \n Dhont\n E,\n \n \n Peperstraete\n H,\n \n \n .\n\t\t\t\t\tAugmented renal clearance: a common condition in critically ill children.\n\t\t\t\t\tPediatr Nephrol.\n\t\t\t\t\t2019;\n\t\t\t\t\t34(\n\t\t\t\t\t6):\n\t\t\t\t\t1099\u2013\n\t\t\t\t\t1106."},{"issue":"3","key":"i2331-348X-27-5-419-b38","series-title":"Ther Drug Monit","first-page":"393","article-title":"Augmented renal clearance in pediatric patients with febrile neutropenia associated with vancomycin clearance","volume":"38","year":"2016","unstructured":"Hirai\n K,\n \n \n Ihara\n S,\n \n \n Kinae\n A,\n \n \n .\n\t\t\t\t\tAugmented renal clearance in pediatric patients with febrile neutropenia associated with vancomycin clearance.\n\t\t\t\t\tTher Drug Monit.\n\t\t\t\t\t2016;\n\t\t\t\t\t38(\n\t\t\t\t\t3):\n\t\t\t\t\t393\u2013\n\t\t\t\t\t397."},{"issue":"4","key":"i2331-348X-27-5-419-b39","series-title":"Braz J Infect Dis","first-page":"361","article-title":"Vancomycin serum concentrations in pediatric oncologic\/hematologic intensive care patients","volume":"16","year":"2012","unstructured":"Silva\n DC,\n \n \n Seixas\n GT,\n \n \n Araujo\n OR,\n \n \n .\n\t\t\t\t\tVancomycin serum concentrations in pediatric oncologic\/hematologic intensive care patients.\n\t\t\t\t\tBraz J Infect Dis.\n\t\t\t\t\t2012;\n\t\t\t\t\t16(\n\t\t\t\t\t4):\n\t\t\t\t\t361\u2013\n\t\t\t\t\t365."},{"issue":"3","key":"i2331-348X-27-5-419-b40","series-title":"Burns","first-page":"445","article-title":"Individualised vancomycin doses for paediatric burn patients to achieve PK\/PD targets","volume":"39","year":"2013","unstructured":"Gomez\n DS,\n \n \n Campos\n EV,\n \n \n de Azevedo\n RP,\n \n \n .\n\t\t\t\t\tIndividualised vancomycin doses for paediatric burn patients to achieve PK\/PD targets.\n\t\t\t\t\tBurns.\n\t\t\t\t\t2013;\n\t\t\t\t\t39(\n\t\t\t\t\t3):\n\t\t\t\t\t445\u2013\n\t\t\t\t\t450."}],"container-title":["The Journal of Pediatric Pharmacology and Therapeutics"],"original-title":[],"link":[{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/27\/5\/article-p419.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/meridian.allenpress.com\/jppt\/article-pdf\/27\/5\/419\/3083935\/i2331-348x-27-5-419.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jppt.kglmeridian.com\/downloadpdf\/journals\/jppt\/27\/5\/article-p419.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jppt.kglmeridian.com\/downloadpdf\/journals\/jppt\/27\/5\/article-p419.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:35:19Z","timestamp":1747355719000},"score":1,"resource":{"primary":{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/27\/5\/article-p419.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":40,"journal-issue":{"issue":"5"},"URL":"https:\/\/doi.org\/10.5863\/1551-6776-27.5.419","relation":{},"ISSN":["2331-348X","1551-6776"],"issn-type":[{"value":"2331-348X","type":"electronic"},{"value":"1551-6776","type":"print"}],"subject":[],"published":{"date-parts":[[2022]]}}}